Man Uses AI to Design Cancer Vaccine for His Dog, Extending Her Life

A remarkable citizen science project has shown the potential of AI-driven personalised medicine.

Paul Conyngham was running out of options. His dog, Rosie—an Australian Staffordshire crossbred Shar Pei—had been diagnosed with mast cell cancer about two years ago. Despite multiple surgeries, immunotherapy, and targeted therapies, the cancer persisted.

"The vaccine shrank tumours on Rosie's legs, extending her life by several months, though she still has cancer."

In a bold move, Conyngham turned to AI chatbots to process genetic data for an mRNA vaccine. The vaccine was designed by scientists at the University of New South Wales (UNSW). The result? Tumours on Rosie's legs shrank, buying her several extra months of life.

A New Approach to an Old Problem

The project highlights a major shift in how medical treatments could be developed. UNSW Professor Pall Thordarson noted that AI streamlined the design process and reduced manufacturing mistakes. However, he pointed out a critical bottleneck:

"Current regulatory frameworks, established 50–100 years ago, are outdated. Australia could take the lead in precision medicine with political decisions."

UNSW Professor Martin Smith echoed this sentiment. He highlighted that the project shortened development from years and millions of dollars to just months. But he called for better support to operationalize such personalized therapies into clinical practice.

The Science Behind the Breakthrough

Developing a personalised vaccine requires DNA sequencing unique to each patient's tumour. This is a complex and expensive process. Under current rules:

• Each new vaccine must undergo full regulatory approval
• That approval process can take 5–10 years

This timeline is a major obstacle for life-saving treatments. Professor Smith warned that Australia lags in cancer genomics and that additional investment is needed to move from research to practice.

"The project was a citizen science initiative, not a clinical trial."

Political Interest

The approach has even caught the attention of US policymakers. US Health Secretary Robert F Kennedy Jr expressed excitement about the method at a Senate hearing in April.

Looking Ahead

While Rosie's case is a powerful proof of concept, it also raises urgent questions. Without updated regulations and dedicated funding, treatments like these—which could save both human and animal lives—may remain out of reach for most patients.

The message from the scientists is clear: The technology is ready. The system is not.